MedTrace Logo

Laser Therapy for Vulvovaginal Symptoms in Breast Cancer Patients

NCT03628092 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2020-03-12

No results posted yet for this study

Summary

To determine the efficacy of ablative carbon dioxide laser in the treatment of the signs and symptoms of vulvovaginal atrophy (VVA) or genitourinary syndrome of menopause (GSM) in women with breast cancer.

Conditions

  • Vulvovaginal Atrophy
  • Genitourinary Symptoms and Ill-Defined Conditions

Interventions

DEVICE

CO2 Fractional Ablative Laser

Vaginal / vulval laser treatment

DEVICE

Placebo

Sham Device

Sponsors & Collaborators

  • Royal North Shore Hospital

    lead OTHER

Principal Investigators

  • Antonia Pearson, BMed · Royal North Shore Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-24
Primary Completion
2020-07-01
Completion
2021-10-01

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03628092 on ClinicalTrials.gov